ImmunoCellular Therapeutics: Explaining The Benefits Of A Multiple Antigen Targeting Approach

Jason Chew submits: In the last few years, tremendous progress has been made in the field of active immunotherapy for oncology. Commonly known as cancer vaccines, this promising field has felt the sting of failure all too often. Then in 2010 with the approval of Provenge, a fire was relit as interest returned. Newer, better cancer vaccines are now coming to fruition, and the results are eye-popping.

Jacob Wolinsky submits: Ever since the approval of Provenge six months ago crowned Dendreon (DNDN) the king of cancer vaccines, investors have been browsing biotech high and low for its prince.

Edward Stevenson submits:As the first FDA-approved immunotherapy, Dendreon's (DNDN) Provenge significantly reduced the barriers to entry for firms seeking regulatory approval of immune-based therapies. The first mover advantage also scored Dendreon a lofty $6.12B valuation.

Mike Havrilla submits:Griffin Securities issued an updated research report today on ImmunoCellular Therapeutics (IMUC.OB), which includes a price objective of $3.25 per share.

Jacob Wolinsky submits: I am compensated for research coverage, which denotes a clear bias in my investment opinion. I believe that my research is objective, weighing both the risks and rewards of an investment opportunity. However, my end goal is to highlight firms that I believe are innovative and offer compelling investment propositions.

Edward Stevenson submits:Less than two years ago, Dendreon's (DNDN) Provenge, an active cellular immunotherapy treatment for prostate cancer, was proven to prolong the survival rate of patients receiving the remedy in a series of controlled clinical trials. According to the company's data:

By Grant Zeng: Currently, there are a bunch of small cap biotech companies which are involved in cancer immunotherapies. But only a few catch investors’ eyes. ImmunoCellular Therapeutics (IMUC.OB) is one of them. ImmunoCellular Therapeutics stands out for a couple of reasons. ImmunoCellular Therapeutics is at the forefront of targeting cancer stem cells

By Timeless Wealth:Standard of care therapy for 10,000+ diagnosed with glioblastoma multiforme (GBM) each year in the United States shows a median survival rate of 26.5%, two years following treatment. An initial study of ICT-107, a dendritic cell-based vaccine for the treatment of GBM, showed 80.2% of patients were alive at the two-year mark.